ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013
Existing and emerging technologies for tumor genomic profiling.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed.
- Trial
- Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.NPJ breast cancer · 2026Article
- The treatment of breast cancer in the era of precision medicine.Cancer biology & medicine · 2025Review
- Unveiling the Digital Evolution of Molecular Tumor Boards.Targeted oncology · 2025Review
- Currently available molecular analyses for personalized tumor therapy (Review).Biomedical reports · 2022Review
- Accuracy of next-generation sequencing for molecular profiling of small specimen of lung cancer: a prospective pilot study of side-by-side comparison.Diagnostic pathology · 2022Article
- Impact of Molecular Tumor Board on the Clinical Management of Patients With Cancer.JCO global oncology · 2022Article
- Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2022Article
- Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations.Cancer research and treatment · 2022Article
- Community oncologists' perceptions and utilization of large-panel genomic tumor testing.BMC cancer · 2021Article
- Physician Communication and Patient Understanding of Molecular Testing Terminology.The oncologist · 2021Article
- Precision Oncology Beyond Genomics: The Future Is Here-It Is Just Not Evenly Distributed.Cells · 2021Review
- Article
- Incidence of theCancers · 2021Article
- Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.PloS one · 2021Article
- Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden.Molecular oncology · 2020Article
- Precision Genomic Practice in Oncology: Pharmacist Role and Experience in an Ambulatory Care Clinic.Pharmacy (Basel, Switzerland) · 2020Article
- Characteristics of Patients WithJCO oncology practice · 2020Article
- DeepLRHE: A Deep Convolutional Neural Network Framework to Evaluate the Risk of Lung Cancer Recurrence and Metastasis From Histopathology Images.Frontiers in genetics · 2020Article
- A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.International journal of breast cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Ongoing global genome characterization efforts are revolutionizing our knowledge of cancer genomics and tumor biology. In parallel, information gleaned from these studies on driver cancer gene alterations--mutations, copy number alterations, translocations, and/or chromosomal rearrangements--an be leveraged, in principle, to develop a cohesive framework for individualized cancer treatment. These possibilities have been enabled, to a large degree, by revolutionary advances in genomic technologies that facilitate systematic profiling for hallmark cancer genetic alterations at increasingly fine resolutions. Ongoing innovations in existing genomics technologies, as well as the many emerging technologies, will likely continue to advance translational cancer genomics and precision cancer medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.